Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Journal of Immunology Research Year : 2017

Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy


Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.


Fichier principal
Vignette du fichier
ArticleBirkleEq14.pdf (1.5 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-01474322 , version 1 (22-02-2017)



Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, et al.. Targeting-Acetyl-GD2 Ganglioside for Cancer Immunotherapy. Journal of Immunology Research, 2017, 2017, [Epub ahead of print]. ⟨10.1182/blood-2013-11-541235⟩. ⟨inserm-01474322⟩
229 View
242 Download



Gmail Facebook X LinkedIn More